Trial
NCT03410927
A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities
Phase ITERMINATEDSAFETYConfidence: HIGH
Sponsor
Taiho Oncology, Inc.
Collaborators
—
Condition
Advanced Solid Tumors With HER2 Abnormalities
Intervention
TAS0728
Why stopped
The study was stopped due to unacceptable toxicity during the dose-escalation portion (Phase 1) of the study and did not progress to Phase 2
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-09-05